Table 3. Number of patients with eGFR-based chronic kidney disease (CKD) and a CKD diagnosis code, the proportion that occurred on or after their second qualifying eGFR measurement and the time between the second qualifying eGFR measurement and entry of a diagnostic code

Variable	Group	Patients, n	Diagnosis code after eGFR-based CKD, n (%)	Median time from eGFR-based CKD to CKD diagnosis code, months (IQR)
Age group, years
	<40	3	1 (33.3)	0.7 (0.7–0.7)
	40–49	19	11 (57.9)	2.9 (1.9–9.6)
	50–59	111	56 (50.5)	8.9 (1.1–16.3)
	60–69	298	156 (52.3)	10.9 (2.0–28.2)
	70–79	496	293 (59.1)	9.9 (1.0–24.8)
	≥80	283	151 (53.4)	8.9 (0.9–20.6)
Sex
	Female	566	319 (56.4)	10.6 (1.1–24.1)
	Male	644	349 (54.2)	9.0 (1.2–24.3)
Duration of T2DM
	<1 year	77	48 (62.3)	11.8 (0.8–26.2)
	1–2 years	69	44 (63.8)	10.1 (2.0–27.2)
	2–5 years	177	94 (53.1)	7.6 (0.7–26.1)
	5–10 years	359	179 (49.9)	9.7 (1.1–21.4)
	>10 years	528	303 (57.4)	10.2 (1.5–23.2)
CKD stage
	G3A	1025	569 (55.5)	9.9 (1.2–25.3)
	G3B	139	78 (56.1)	10.2 (1.2–20.4)
	G4	38	17 (44.7)	7.3 (0.7–16.6)
	G5	8	4 (50.0)	7.2 (2.8–21.5)
Total	Overall	1210	668 (55.2)	9.8 (1.2–24.3)

eGFR = estimated glomerular filtration rate. CKD = chronic kidney disease. IQR = interuartile range. T2DM = type 2 diabetes mellitus.